Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
3 Dow Stocks Poised for a Roaring Relief Rally
02:03pm, Friday, 26'th May 2023
It may seem crazy to talk about stocks having a relief rally. But even if you're the biggest skeptic, you should look at the components of the Dow Jones Industrial Average.
Solid Earnings Fuel Potential Bull Market in Medical Devices
11:05am, Friday, 26'th May 2023
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
Want Passive Income Forever? Buy These 2 Magnificent Stocks Now
09:53am, Friday, 26'th May 2023
These two companies are leaders in their respective industries with a long history of success. Both have a habit of delivering solid financial results and increasing their dividend payouts.
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
05:30am, Friday, 26'th May 2023
Johnson & Johnson's Stelara, which brought in more than $9 billion in sales last year, is on its way to losing exclusivity. J&J has been through this before, with another immunology drug called Remica
My Top 10 High Dividend Yield Companies For June 2023
06:00pm, Thursday, 25'th May 2023
High dividend yield companies can help you earn an extra income in the form of dividends, which you can then use to cover your expenses. In this article, I will introduce you to 10 companies that I be
Medical technology is a good space for cover in recession times, says Mizuho's Anthony Petrone
02:52pm, Wednesday, 24'th May 2023
Anthony Petrone, senior medical devices analyst at Mizuho, joins 'The Exchange' to discuss medical technology gaining share, the bull case for Medtronic, and how medication advancements could impact t
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
10 A-Rated Dividend Aristocrats For The Ultimate High-Yield SWAN Portfolio
07:20am, Wednesday, 24'th May 2023
The debt ceiling crisis is coming down to the wire. We're possibly already out of time to prevent default and just don't know it. UBS estimates a short default could create a 20% bear market and a one
Better Buy: Medtronic vs. Johnson & Johnson
05:30am, Wednesday, 24'th May 2023
Medtronic is going through an “aggressive transformation” to boost growth. J&J is spinning off its consumer health business to focus on its higher-growth businesses.
7 Safe-Haven Stocks to Buy for Protection From a U.S. Debt Default Disaster
07:18pm, Tuesday, 23'rd May 2023
With the debt ceiling issue rating as perhaps the single-most critical issue for the market right now, investors should consider targeting safe-haven stocks for debt default. Naturally, the U.S. gover
Report of new COVID wave in China pushes shares of vaccine makers higher
05:32pm, Tuesday, 23'rd May 2023
Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the
Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara
10:29am, Tuesday, 23'rd May 2023
Johnson & Johnson's Janssen Biotech Inc has settled its lawsuit against Amgen Inc over Amgen's proposed similar version of J&J's top-selling drug Stelara, according to a filing Monday in Delaware fede
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
10:07am, Tuesday, 23'rd May 2023
Johnson & Johnson has grown revenue for seven consecutive years. Dollar General's discount stores are often in underserved areas.
Will Dividends Take Center Stage In The Second Half Of 2023?
07:02am, Tuesday, 23'rd May 2023
Plenty of individual stocks are notching outsized gains this year, with S&P 500 leaders Nvidia Corp. NASDAQ: NVDA and Meta Platforms Inc. NASDAQ: META more than doubling in price. Advanced Micro Devic
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
06:14am, Saturday, 20'th May 2023
AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid.
